Increase in Investment toward Development of New Singapore Vaccines is Expected to Drive the Market


Vaccine Market Outlook

The growth of the global Singapore vaccine market is attributed to increase in incidence of infectious diseases and promising vaccines in late stage of pipeline majorly drives the market growth. Furthermore, surge in investments by government on immunization programs and rise in awareness for immunization in developing countries further contribute toward the growth of the market.

High prevalence of diseases requiring administration of Singapore vaccines and emerging use of vaccines for different infectious diseases, such as influenza, pneumonia, and rotavirus infection, are expected to drive the growth of the global vaccines market. In addition, focus of governments on immunization programs aids in creating awareness among people about safety and availability of vaccines. Further, different technologies employed in the development of effective vaccines boost the vaccine market growth. However, it takes approximately 11–12 years for a single vaccine to be introduced in the commercial market. These prolonged procedural timelines of vaccine development restrain the development of new vaccines; thereby, hampering the market growth. In addition, high monetary inputs in the development of vaccines decrease their adoption, limiting the growth further

COVID-19 scenario : 

Most of the markets are dropping down, owing to the outbreak, including the Singapore vaccine market. The global vaccine market is negatively impacted by the pandemic as most countries adopted lockdown to combat the pandemic. In addition, most of the leading companies across the globe have slow down the manufacturing of other vaccines. Furthermore, the individual contributions companies are collaborating to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19.

Key segments covered:

By Technology type

  • Recombinant & Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus {DPT}
  • Polio
  • Hepatitis
  • Other Indications

Companies covered

  • Serum Institute of India Pvt. Ltd.
  • Pfizer
  • Johnson & Johnson
  • AstraZenecea plc
  • GlaxoSmithKline plc
  • Sanofi Aventis
  • Merck & Co., Inc.
  • Emergent BioSolutions Inc.
  • CSL Limited, Novavax, Inc.

have better knowledge about vaccine Market 

Post a Comment